{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:21Z","timestamp":1772165661028,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068614"],"award-info":[{"award-number":["UM1 AI068614"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068635"],"award-info":[{"award-number":["UM1 AI068635"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI069412"],"award-info":[{"award-number":["UM1 AI069412"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pregnancies occur during HIV-1 vaccine clinical trials, despite requirements for women of reproductive potential to use effective contraception. Deployment of an effective HIV-1 vaccine regimen will likely target adolescents and young adults and therefore safety for pregnant and breastfeeding women will need to be addressed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective, cross-protocol analysis to identify and compare pregnancy outcomes reported in 53 Phase 1 and Phase 2a HIV-1 vaccine clinical trials conducted by the HIV Vaccine Trials Network (HVTN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two thousand six hundred seventy-three women of reproductive potential were identified and 193 pregnancies were reported. 39 of 53 (74%) studies had at least one pregnancy reported with an overall pregnancy rate of 3.15 per 100 woman-years (w-yr). While active contraception use was required during study participation, 13 of the 53 studies also contained a long-term follow up period during which pregnancy was no longer discouraged. The pregnancy rate during main study participation was 3.09 per 100 w-yr, while pregnancies occurred at a slightly greater rate in the long-term follow up period (3.22 per 100 w-yr). Adverse pregnancy outcomes were reported at similar rates between vaccinees and placebo recipients when vaccine vectors, adjuvant used, or geographic region were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although there is considerable heterogeneity amongst the different vaccine trials, there appears to be no obvious indication of increased risk of adverse pregnancy or birth outcomes in these early phase HIV-1 vaccine studies. More complete data on pregnancy outcomes should be collected in early phase HIV-1 vaccine clinical trials to better inform subsequent efficacy trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-06431-x","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T09:03:44Z","timestamp":1628672624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A retrospective analysis of incident pregnancy in phase 1 and 2a HIV-1 vaccine study participants does not support concern for adverse pregnancy or birth outcomes"],"prefix":"10.1186","volume":"21","author":[{"given":"Lynda","family":"Stranix-Chibanda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenchen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret Brewinski","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Andriesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-9370","authenticated-orcid":false,"given":"Stephen R.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"key":"6431_CR1","unstructured":"UNAIDS 2019 Estimates. http:\/\/aidsinfo.unaids.org\/"},{"key":"6431_CR2","doi-asserted-by":"publisher","unstructured":"Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy and postpartum and risk of mother-to-Child HIV transmission: a systematic review and meta-analysis. Mofenson LM, ed. PLoS Med. 2014;11(2):e1001608. doi:https:\/\/doi.org\/10.1371\/journal.pmed.1001608","DOI":"10.1371\/journal.pmed.1001608"},{"issue":"1","key":"6431_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/infdis\/jiy113","volume":"218","author":"KA Thomson","year":"2018","unstructured":"Thomson KA, Hughes J, Baeten JM, John-Stewart G, Celum C, Cohen CR, et al. Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis among women with HIV-infected partners. J Infect Dis. 2018;218(1):16\u201325. https:\/\/doi.org\/10.1093\/infdis\/jiy113.","journal-title":"J Infect Dis"},{"key":"6431_CR4","doi-asserted-by":"publisher","unstructured":"Joseph Davey D, Farley E, Gomba Y, Coates T, Myer L. Sexual risk during pregnancy and postpartum periods among HIV-infected and \u2013uninfected South African women: Implications for primary and secondary HIV prevention interventions. Yotebieng M, ed. PLOS ONE. 2018;13(3):e0192982. doi:https:\/\/doi.org\/10.1371\/journal.pone.0192982","DOI":"10.1371\/journal.pone.0192982"},{"issue":"1","key":"6431_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/infdis\/jiy118","volume":"218","author":"LM Mofenson","year":"2018","unstructured":"Mofenson LM. Risk of HIV acquisition during pregnancy and postpartum: a call for action. J Infect Dis. 2018;218(1):1\u20134. https:\/\/doi.org\/10.1093\/infdis\/jiy118.","journal-title":"J Infect Dis"},{"key":"6431_CR6","doi-asserted-by":"publisher","unstructured":"Dinh T-H, Delaney KP, Goga A, et al. Impact of maternal HIV seroconversion during pregnancy on early mother to child transmission of HIV (MTCT) measured at 4\u20138 weeks postpartum in South Africa 2011\u20132012: A national population-based evaluation. Davies M-A, ed. Plos One. 2015;10(5):e0125525. doi:https:\/\/doi.org\/10.1371\/journal.pone.0125525","DOI":"10.1371\/journal.pone.0125525"},{"issue":"12","key":"6431_CR7","doi-asserted-by":"publisher","first-page":"e688","DOI":"10.1016\/S2352-3018(18)30316-3","volume":"5","author":"BA Tippett Barr","year":"2018","unstructured":"Tippett Barr BA, van Lettow M, van Oosterhout JJ, Landes M, Shiraishi RW, Amene E, et al. National estimates and risk factors associated with early mother-to-child transmission of HIV after implementation of option B+: a cross-sectional analysis. Lancet HIV. 2018;5(12):e688\u201395. https:\/\/doi.org\/10.1016\/S2352-3018(18)30316-3.","journal-title":"Lancet HIV"},{"key":"6431_CR8","unstructured":"UNAIDS. Ethical Considerations in HIV Preventive Vaccine Research\u00a0: UNAIDS Guidance Document.; 2000. http:\/\/data.unaids.org\/publications\/irc-pub01\/jc072-ethicalcons_en.pdf"},{"key":"6431_CR9","unstructured":"International AIDS Vaccine Initiative. UNDERSTANDING THE RECRUITMENT AND RETENTION OF WOMEN IN CLINICAL TRIALS - what are some of THE considerations regarding recruitment and retention of women in AIDS vaccine clinical trials?; 2015. https:\/\/www.vaxreport.org\/vax-march-2008\/657-understanding-the-recruitment-and-retention-of-women-in-clinical-trials"},{"issue":"5","key":"6431_CR10","doi-asserted-by":"publisher","first-page":"e0216332","DOI":"10.1371\/journal.pone.0216332","volume":"14","author":"KA Sullivan","year":"2019","unstructured":"Sullivan KA, Little MO, Rosenberg NE, Zimba C, Jaffe E, Gilbert S, et al. Women\u2019s views about contraception requirements for biomedical research participation. PLoS One. 2019;14(5):e0216332. https:\/\/doi.org\/10.1371\/journal.pone.0216332.","journal-title":"PLoS One"},{"key":"6431_CR11","doi-asserted-by":"publisher","unstructured":"Latka MH, Fielding K, Gray GE, et al. Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women. Kissinger P, ed. Plos One. 2012;7(4):e31387. doi:https:\/\/doi.org\/10.1371\/journal.pone.0031387","DOI":"10.1371\/journal.pone.0031387"},{"key":"6431_CR12","unstructured":"Clayton A, Andriessen J, Kublin JG. A Treasure Trove of Clinical Specimens and Data: Mining Research Opportunities With the HIV Vaccine Trials Network (HVTN). Satellite Session, HIVR4P 2018.; 2018. http:\/\/webcasts.hivr4p.org\/"},{"issue":"40","key":"6431_CR13","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2013.07.003","volume":"31","author":"MP Andrasik","year":"2013","unstructured":"Andrasik MP, Karuna ST, Nebergall M, Koblin BA, Kublin JG. Behavioral risk assessment in HIV vaccine trials network (HVTN) clinical trials: a qualitative study exploring HVTN staff perspectives. Vaccine. 2013;31(40):4398\u2013405. https:\/\/doi.org\/10.1016\/j.vaccine.2013.07.003.","journal-title":"Vaccine."},{"issue":"1","key":"6431_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2307\/2340521","volume":"85","author":"RA Fisher","year":"1922","unstructured":"Fisher RA. On the interpretation of \u03c72 from contingency tables, and the calculation of P. J R Stat Soc. 1922;85(1):87\u201394. https:\/\/doi.org\/10.2307\/2340521.","journal-title":"J R Stat Soc"},{"issue":"8","key":"6431_CR15","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1080\/21645515.2016.1186312","volume":"12","author":"JA Beeler","year":"2016","unstructured":"Beeler JA, Lambach P, Fulton TR, Narayanan D, Ortiz JR, Omer SB. A systematic review of ethical issues in vaccine studies involving pregnant women. Hum Vaccines Immunother. 2016;12(8):1952\u20139. https:\/\/doi.org\/10.1080\/21645515.2016.1186312.","journal-title":"Hum Vaccines Immunother."},{"issue":"2","key":"6431_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/21645515.2017.1264773","volume":"13","author":"G Gabutti","year":"2017","unstructured":"Gabutti G, Conforti G, Tomasi A, Kuhdari P, Castiglia P, Prato R, et al. Why, when and for what diseases pregnant and new mothers \u201cshould\u201d be vaccinated. Hum Vaccines Immunother. 2017;13(2):283\u201390. https:\/\/doi.org\/10.1080\/21645515.2017.1264773.","journal-title":"Hum Vaccines Immunother"},{"issue":"52","key":"6431_CR17","doi-asserted-by":"publisher","first-page":"7057","DOI":"10.1016\/j.vaccine.2014.09.052","volume":"32","author":"B Keller-Stanislawski","year":"2014","unstructured":"Keller-Stanislawski B, Englund JA, Kang G, Mangtani P, Neuzil K, Nohynek H, et al. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine. 2014;32(52):7057\u201364. https:\/\/doi.org\/10.1016\/j.vaccine.2014.09.052.","journal-title":"Vaccine."},{"issue":"4","key":"6431_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1086\/422258","volume":"190","author":"S Nitayaphan","year":"2004","unstructured":"Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M, Morgan P, et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis. 2004;190(4):702\u20136. https:\/\/doi.org\/10.1086\/422258.","journal-title":"J Infect Dis"},{"issue":"11","key":"6431_CR19","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1089\/aid.2012.0265","volume":"29","author":"J Kaewkungwal","year":"2013","unstructured":"Kaewkungwal J, Pitisuttithum P, Rerks-ngarm S, Nitayaphan S, Khamboonruang C, Kunasol P, et al. Issues in Women\u2019s participation in a phase III Community HIV vaccine trial in Thailand. AIDS Res Hum Retrovir. 2013;29(11):1524\u201334. https:\/\/doi.org\/10.1089\/aid.2012.0265.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"7","key":"6431_CR20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S1473-3099(11)70098-6","volume":"11","author":"GE Gray","year":"2011","unstructured":"Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011;11(7):507\u201315. https:\/\/doi.org\/10.1016\/S1473-3099(11)70098-6.","journal-title":"Lancet Infect Dis"},{"key":"6431_CR21","unstructured":"Skoler S. Our current microbicide trials: lessons learned and to be learned. Published online March 2006. https:\/\/pdfs.semanticscholar.org\/7ef9\/3d800815b3cdad9c2f88a54d9a7b28f89aac.pdf?_ga=2.183211366.1917707118.1573405587-1131198800.1562267537"},{"key":"6431_CR22","doi-asserted-by":"publisher","unstructured":"Kibuuka H, Guwatudde D, Kimutai R, et al. Contraceptive use in women enrolled into Preventive HIV vaccine trials: experience from a phase I\/II trial in East Africa. Galvani AP, ed. Plos One. 2009;4(4):e5164. doi:https:\/\/doi.org\/10.1371\/journal.pone.0005164","DOI":"10.1371\/journal.pone.0005164"},{"key":"6431_CR23","unstructured":"PRGLAC Task Force. Task Force on Research Specific to Pregnant Women and Lactating Women - Report to Secretary, Health and Human Services, Congress.; 2018. https:\/\/www.nichd.nih.gov\/sites\/default\/files\/2018-09\/PRGLAC_Report.pdf"},{"issue":"3","key":"6431_CR24","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1371\/journal.pmed.0030094","volume":"3","author":"E Mills","year":"2006","unstructured":"Mills E, Nixon S, Singh S, Dolma S, Nayyar A, Kapoor S. Enrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge. PLoS Med. 2006;3(3):e94. https:\/\/doi.org\/10.1371\/journal.pmed.0030094.","journal-title":"PLoS Med"},{"issue":"49","key":"6431_CR25","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1016\/j.vaccine.2016.07.006","volume":"34","author":"J Bonhoeffer","year":"2016","unstructured":"Bonhoeffer J, Kochhar S, Hirschfeld S, Heath PT, Jones CE, Bauwens J, et al. Global alignment of immunization safety assessment in pregnancy \u2013 the GAIA project. Vaccine. 2016;34(49):5993\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2016.07.006.","journal-title":"Vaccine."},{"key":"6431_CR26","unstructured":"Brighton Collaboration Foundation. Brighton Collaboration - for a safe immunization in the world. https:\/\/www.brightoncollaboration.org\/."},{"issue":"48","key":"6431_CR27","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1016\/j.vaccine.2017.01.040","volume":"35","author":"EP Schlaudecker","year":"2017","unstructured":"Schlaudecker EP, Munoz FM, Bardaj\u00ed A, Boghossian NS, Khalil A, Mousa H, et al. Small for gestational age: case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. Vaccine. 2017;35(48):6518\u201328. https:\/\/doi.org\/10.1016\/j.vaccine.2017.01.040.","journal-title":"Vaccine."},{"key":"6431_CR28","unstructured":"US Food and Drug Administration (FDA). List of pregnancy registries. Women\u2019s Health Research. https:\/\/www.fda.gov\/science-research\/womens-health-research\/list-pregnancy-exposure-registries."},{"issue":"11","key":"6431_CR29","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1001\/jama.2021.1865","volume":"325","author":"DW Bianchi","year":"2021","unstructured":"Bianchi DW, Kaeser L, Cernich AN. Involving pregnant individuals in clinical research on COVID-19 vaccines. JAMA. 2021;325(11):1041\u20132. https:\/\/doi.org\/10.1001\/jama.2021.1865.","journal-title":"JAMA."},{"key":"6431_CR30","doi-asserted-by":"publisher","first-page":"m3305","DOI":"10.1136\/bmj.m3305","volume":"370","author":"M Knight","year":"2020","unstructured":"Knight M, Morris RK, Furniss J, Chappell LC. Include pregnant women in research\u2014particularly covid-19 research. BMJ. 2020;370:m3305. https:\/\/doi.org\/10.1136\/bmj.m3305.","journal-title":"BMJ."},{"issue":"3","key":"6431_CR31","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1016\/S2214-109X(20)30484-8","volume":"9","author":"MM Taylor","year":"2021","unstructured":"Taylor MM, Kobeissi L, Kim C, Amin A, Thorson AE, Bellare NB, et al. Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action. Lancet Glob Health. 2021;9(3):e366\u201371. https:\/\/doi.org\/10.1016\/S2214-109X(20)30484-8.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"6431_CR32","doi-asserted-by":"publisher","first-page":"e2037640","DOI":"10.1001\/jamanetworkopen.2020.37640","volume":"4","author":"LE Flores","year":"2021","unstructured":"Flores LE, Frontera WR, Andrasik MP, del Rio C, Mondr\u00edguez-Gonz\u00e1lez A, Price SA, et al. Assessment of the inclusion of racial\/ethnic minority, female, and older individuals in vaccine clinical trials. JAMA Netw Open. 2021;4(2):e2037640. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.37640.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"6431_CR33","doi-asserted-by":"publisher","first-page":"e0239276","DOI":"10.1371\/journal.pone.0239276","volume":"15","author":"GB Broder","year":"2020","unstructured":"Broder GB, Lucas JP, Davis J, Wallace SE, Luthuli N, Baepanye K, et al. Standardized metrics can reveal region-specific opportunities in community engagement to aid recruitment in HIV prevention trials. PLoS One. 2020;15(9):e0239276. https:\/\/doi.org\/10.1371\/journal.pone.0239276.","journal-title":"PLoS One"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06431-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06431-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06431-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T09:03:48Z","timestamp":1628672628000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06431-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6431"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06431-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-23939\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,11]]},"assertion":[{"value":"21 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The series of trials included in this analysis obtained ethical approval from the required regulatory bodies prior to activation and individual informed consent was provided by all trial participants. Institutional approval for this secondary analysis was obtained from the Partners Human Research Committee (Massachusetts General\/Brigham & Women\u2019s Institutional Review Board), protocol number 2018P001027.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SRW has received clinical trial support from Janssen Vaccines for unrelated HIV vaccine work; LSC, JA, CY, MA, and MBI declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"802"}}